The same mutation in a family with adenosine deaminase 2 deficiency

Rheumatol Int. 2021 Jan;41(1):227-233. doi: 10.1007/s00296-019-04444-z. Epub 2019 Sep 20.

Abstract

The deficiency of adenosine deaminase 2 (DADA2) has recently been defined as a monogenetic autosomal recessive autoinflammatory disease. DADA2 is mainly characterized by high fever, livedo racemose, early-onset stroke, mild immunodeficiency and clinically polyarteritis nodosa (PAN)-like symptoms. Mutations in CECR1 (cat eye syndrome chromosome region, candidate 1) are responsible for DADA2. Livedoid racemose, lacunar infarct due to involvement in small vessel of the central nervous system, peripheral neuropathy, digital ulcers and loss of fingers are predominantly seen in the disease which could progress to end-stage organ failure and death in some patients. A wide spectrum of severity in phenotype as well as in the age of onset has been reported in the literature. This phenotypic variability is also found in our clinical practice even in patients with the same mutation. Here, we present a family diagnosed with DADA2, with the previously reported p.Gly47Arg mutation in CECR1.

Keywords: Adenosine deaminase 2 deficiency; Polyarteritis nodosa and CECR1.

Publication types

  • Case Reports
  • Review

MeSH terms

  • Adolescent
  • Adrenal Cortex Hormones / therapeutic use
  • Adult
  • Agammaglobulinemia / complications
  • Agammaglobulinemia / diagnosis*
  • Agammaglobulinemia / drug therapy
  • Age of Onset
  • Child
  • Child, Preschool
  • Family
  • Female
  • Genetic Predisposition to Disease
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Male
  • Pedigree
  • Polyarteritis Nodosa / etiology*
  • Severe Combined Immunodeficiency / complications
  • Severe Combined Immunodeficiency / diagnosis*
  • Severe Combined Immunodeficiency / drug therapy

Substances

  • Adrenal Cortex Hormones
  • Immunosuppressive Agents

Supplementary concepts

  • Severe combined immunodeficiency due to adenosine deaminase deficiency